Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Infertility: HELP
Articles by Thibault de La Motte Rouge
Based on 3 articles published since 2008
||||

Between 2008 and 2019, Thibault de la Motte Rouge wrote the following 3 articles about Infertility.
 
+ Citations + Abstracts
1 Guideline [Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumors: Guidelines from the French national network dedicated to rare gynaecological cancer]. 2018

Rousset-Jablonski, Christine / Selle, Fréderic / Adda-Herzog, Elodie / Planchamp, François / Selleret, Lise / Pomel, Christophe / Chabbert-Buffet, Nathalie / Daraï, Emile / Pautier, Patricia / Trémollières, Florence / Guyon, Frederic / Rouzier, Roman / Laurence, Valérie / Chopin, Nicolas / Faure-Conter, Cécile / Bentivegna, Enrica / Vacher-Lavenu, Marie-Cécile / Lhomme, Catherine / Floquet, Anne / Treilleux, Isabelle / Lecuru, Fabrice / Gouy, Sébastien / Kalbacher, Elsa / Genestie, Catherine / de la Motte Rouge, Thibault / Ferron, Gwenael / Devouassoux-Shisheboran, Mojgan / Kurtz, Jean-Emmanuel / Namer, Moise / Joly, Florence / Pujade-Lauraine, Eric / Grynberg, Michael / Querleu, Denis / Morice, Philippe / Gompel, Anne / Ray-Coquard, Isabelle. ·Centre Léon-Bérard, 28, rue Laënnec, 69008 Lyon, France; Hospices civils de Lyon, centre hospitalier Lyon-Sud, 165, chemin du grand-Revoyet, 69495 Pierre-Bénite cedex, France. Electronic address: christine.rousset-jablonski@lyon.unicancer.fr. · Groupe hospitalier Diaconesses Croix-Saint-Simon, 12-18, rue du Sergent-Bauchat, 75012 Paris, France. · Hôpital Foch, service de gynécologie-obstétrique, 40, rue Worth, 92151 Suresnes, France. · Institut Bergonié, 229, Cours-de-l'Argonne, 33000 Bordeaux, France. · Hôpital Tenon, service de gynécologie-obstétrique et médecine de la reproduction, 4, rue de la Chine, 75020 Paris, France. · Centre Jean-Perrin, 58, rue Montalembert BP, 392, 63011 Clermont-Ferrand cedex 1, France. · Institut Gustave-Roussy, 114, rue Edouard-Vaillant, 94800 Villejuif, France. · Hôpital Paule-de-Viguier, centre de ménopause et de dépistage de l'ostéoporose, 330, avenue de Grande-Bretagne, TSA 70034, 31059 Toulouse cedex 9, France. · Institut Curie, 26, rue d'Ulm, 75005 Paris, France. · Centre Léon-Bérard, 28, rue Laënnec, 69008 Lyon, France. · Hôpital Cochin-Port Royal, 53, avenue de l'Observatoire, 75014 Paris, France. · Hôpital Européen Geroges-Pompidou, 20, rue Leblanc, 75015 Paris, France. · CHU Besançon-Jean-Minjoz, 3, boulevard Alexandre-Fleming, 25030 Besançon cedex, France. · Centre Eugène-Marquis, avenue de la Bataille-Flandres-Dunkerque, 35000 Rennes, France. · CLCC, institut Claudius-Regaud, IUCT Oncopole, 1, avenue Irène-Joliot-Curie, 31100 Toulouse, France. · Hospices civils de Lyon, centre hospitalier Lyon-Sud, 165, chemin du grand-Revoyet, 69495 Pierre-Bénite cedex, France. · CHU de Strasbourg, hôpital de Hautepierre, avenue Molière, 67200 Strasbourg, France. · Recommandations pour la pratique clinique, Nice-Saint-Paul, 06000 Nice, France. · Centre François-Baclesse, 3, avenue du Général-Harris, 14076 Caen cedex 5, France. · CHU Paris Centre, hôpital Hôtel-Dieu, 1, place du Parvis-Notre-Dame, 75004 Paris, France. · Hôpital Jean-Verdier, avenue du 14 juillet, 93140 Bondy, France. ·Bull Cancer · Pubmed #29397916.

ABSTRACT: INTRODUCTION: Rare ovarian tumors include complex borderline ovarian tumors, sex-cord tumors, germ cell tumors, and rare epithelial tumors. Indications and modalities of fertility preservation, infertility management and contraindications for hormonal contraception or menopause hormone therapy are frequent issues in clinical practice. A panel of experts from the French national network dedicated to rare gynaecological cancers, and of experts in reproductive medicine and gynaecology have worked on guidelines about fertility preservation, contraception and menopause hormone therapy in women treated for ovarian rare tumors. METHODS: A panel of 39 experts from different specialties contributed to the preparation of the guidelines, following the DELPHI method (formal consensus method). Statements were drafted after a systematic literature review, and then rated through two successive rounds. RESULTS: Thirty-five recommendations were selected, and concerned indications for fertility preservation, contraindications for ovarian stimulation (in the context of fertility preservation or for infertility management), contraceptive options (especially hormonal ones), and menopause hormone therapy for each tumor type. Overall, prudence has been recommended in the case of potentially hormone-sensitive tumors such as sex cord tumors, serous and endometrioid low-grade adenocarcinomas, as well as for high-risk serous borderline ovarian tumors. DISCUSSION: In the context of a scarce literature, a formal consensus method allowed the elaboration of guidelines, which will help clinicians in the management of these patients.

2 Review Anticancer treatment and fertility: Effect of therapeutic modalities on reproductive system and functions. 2016

Vassilakopoulou, Maria / Boostandoost, Erfaneh / Papaxoinis, George / de La Motte Rouge, Thibault / Khayat, David / Psyrri, Amanda. ·Service d'Oncologie Médicale, Hôpital de la Pitié-Salpêtrière, 47-83 boulevard de l'Hôpital 75013 Paris, France; Service d'Oncologie Médicale, Hôpital Marc Jacquet, Melun, Seine et Marne, France. Electronic address: marva-1@hotmail.com. · Service d'Oncologie Médicale, Hôpital de la Pitié-Salpêtrière, 47-83 boulevard de l'Hôpital 75013 Paris, France; Service d'Oncologie Médicale, Hôpital Marc Jacquet, Melun, Seine et Marne, France. · Oncology Unit, Second Department of Internal Medicine, Hippocration Hospital, University of Athens, 108V. Sophias, 11634, Greece. · Institut Curie, Hôpital René Huguenin, Service d'Oncologie Médicale, 35 rue Dailly, Saint-Cloud, 92210, France. · Service d'Oncologie Médicale, Hôpital de la Pitié-Salpêtrière, 47-83 boulevard de l'Hôpital 75013 Paris, France. · Oncology Department, Attikon Hospital, University of Athens, 1 Rimini, 12462, Greece. ·Crit Rev Oncol Hematol · Pubmed #26481950.

ABSTRACT: The significant improvement of cancer treatments entailed a longer life in cancer survivors and raised expectations for higher quality of life with minimized long-term toxicity. Infertility and gonadal dysfunction are adverse effects of anticancer therapy or may be related to specific tumors. In female cancer survivors, premature ovarian failure is common after antineoplastic treatments resulting in infertility and other morbidities related to oestrogen deficiency such as osteoporosis. In male cancer survivors, infertility and persistent a zoospermia is a more common long-term adverse effect than hypogonadism because germ cells are more sensitive to chemotherapy and radiotherapy than leydig cells. Gonadal toxicity and compromise of reproductive functions will be more efficiently prevented and treated if addressed before treatment initiation. This review focuses on these issues in young cancer survivors of childbearing age, where methods of protecting or restoring endocrine function and fertility need to be considered.

3 Article Prognostic factors in women treated for ovarian yolk sac tumour: a retrospective analysis of 84 cases. 2011

de La Motte Rouge, Thibault / Pautier, Patricia / Rey, Annie / Duvillard, Pierre / Kerbrat, Pierre / Troalen, Frédéric / Morice, Philippe / Haie-Meder, Christine / Culine, Stéphane / Lhommé, Catherine. ·Department of Medical Oncology, Institut Gustave-Roussy, Villejuif, France. ·Eur J Cancer · Pubmed #20851596.

ABSTRACT: BACKGROUND: Ovarian yolk sac tumour (OYST) is a very rare malignancy arising in young women. Our study aimed to evaluate long-term outcomes and to identify prognostic parameters likely to help make appropriate risk-based decisions about therapy in this disease. METHODS: This retrospective study is based on prospectively recorded OYST cases at the Institut Gustave-Roussy. A univariate analysis using the logrank test evaluated possible associations between survival and patient or disease covariates. The multivariate analysis was performed using the Cox proportional hazard regression method. RESULTS: Between 1976 and 2006, 84 patients were registered. Since 1991, most of the patients have undergone fertility-sparing surgery. With a median follow-up of 71 months, the overall 5-year and event-free survival rates are 84% and 79%, respectively. In the multivariate model only the absence of ascites and a favourable serum AFP decline rate were significantly associated with better overall survival. CONCLUSIONS: Patients with a poor prognosis factor such as an unfavourable serum AFP decline may be considered for aggressive treatment whereas those with good prognostic factors could be given less courses of chemotherapy.